Compared with placebo, sodium zirconium cyclosilicate was associated with less need to lower or discontinue spironolactone.

Many hope My Heart Your Heart will catalyze an effort to help patients worldwide who need but can’t afford these devices.

The India-based trial, the first of its kind, confirmed that systolic BP levels decreased no matter the exact mix of three ...

This session will focus on how AI and computational predictive modeling are reshaping the way we approach TAVR, providing advanced planning techniques and long-term management strategies.

There remains a need to identify patients who will derive benefits from adjunctive techniques on top of pulmonary vein ...

The observed changes were favorable, but results may have been affected by better-than-normal care in the control arm.

In the trial, 20% of patients didn’t respond well to the PCSK9 inhibitor—could genetic markers be used to tailor therapy?

By targeting the TTR gene directly in the liver, the therapy “has opened up the door” to permanent treatment, says Sarah ...

Robert Mentz and C. Michael Gibson discuss the latest trial to address whether iron supplementation, this time with ferric carboxymaltose, improves outcomes for patients with HF and iron deficiency.